quinazolines has been researched along with pf 00299804 in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.67) | 29.6817 |
| 2010's | 27 (90.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Althaus, IW; Bradner, JE; Engelman, JA; Gale, CM; Gandhi, L; Gonzales, AJ; Heymach, JV; Jänne, PA; Lifshits, E; Meyerson, M; Naumov, GN; Nelson, JM; Shapiro, GI; Shimamura, T; Vincent, PW; Wong, KK; Zejnullahu, K; Zhao, F | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Brown, A; Capelletti, M; Christensen, JG; Engelman, JA; Ercan, D; Jänne, PA; Kwiatkowski, DJ; Lee, C; Lifshits, E; Rogers, A; Xiao, Y; Yonesaka, K; Zejnullahu, K | 1 |
| Belani, CP | 1 |
| Ou, SH | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Barrios, CH; Blackhall, F; Bover, I; Boyer, M; Campbell, AK; Frank, R; Krzakowski, M; Letrent, SP; Liang, JQ; O'Connell, J; Park, K; Ramalingam, SS; Rosell, R; Ruiz-Garcia, A; Seog Heo, D; Talbot, DC; Taylor, I | 1 |
| Anderson, L; Britten, CD; Christensen, JG; Cohen, DJ; Conklin, D; Desai, AJ; Finn, RS; Ginther, C; Kalous, O; O'Brien, NA; Slamon, DJ; Taylor, I | 1 |
| Jänne, PA; Oxnard, GR | 1 |
| Cho, BC; Christensen, JG; Ha, SJ; Hong, YK; Kim, JH; Kim, SM; Kwon, OJ; Lee, JH; Solca, F; Soo, RA | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Ather, F; Fejzo, MS; Finn, RS; Hamidi, H; Head, C; Kabbinavar, F; Letrent, S; Wong, SG | 1 |
| Camidge, DR; Campbell, AK; Engelman, JA; Gadgeel, SM; Gernhardt, D; Giaccone, G; Jänne, PA; Khuri, FR; Koczywas, M; Letrent, S; Liang, J; O'Connell, JP; Rajan, A; Reckamp, KL; Ruiz-Garcia, A; Taylor, I | 1 |
| Karachaliou, N; Morales-Espinosa, D; Rosell, R; Viteri, S | 1 |
| Peters, S; Smit, E | 1 |
| Bennouna, J; Boyer, MJ; Docampo, LI; Doherty, JP; Goldberg, Z; Jänne, PA; Liang, JQ; Mather, CB; Mok, T; O'Byrne, K; O'Connell, J; Paz-Ares, L; Pluzanski, A; Ramalingam, SS; Shtivelband, M; Taylor, I; Von Pawel, J; Zhang, H | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Mehra, R; Zibelman, M | 1 |
| Bowen, JM; Gibson, RJ; Van Sebille, YZ; Wardill, HR | 1 |
| Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Elexpuru Zabaleta, M; Galeazzi, R; Gambini, V; Garulli, C; Hysi, A; Iezzi, M; Kalogris, C; Marchini, C; Orlando, F; Pietrella, L; Provinciali, M; Tilio, M; Wang, J | 1 |
| Althaus, IW; Black, SL; Blaser, A; Bridges, A; Denny, WA; Ellis, PA; Ellis, T; Fakhoury, S; Gonzales, AJ; Harvey, PJ; Hook, K; Lee, H; McCarthy, FO; Palmer, BD; Reed, JE; Rivault, F; Schlosser, K; Sexton, K; Smaill, JB; Spicer, JA; Tecle, H; Thompson, AM; Trachet, E; Winters, RT; Zhu, T | 1 |
| Azuma, K; Chiba, M; Kim, YH; Kobayashi, Y; Mitsudomi, T; Nagai, H; Nishio, K; Sato, K; Sesumi, Y; Shimoji, M; Takemoto, T; Togashi, Y; Tomizawa, K | 1 |
| Cho, BC; Doherty, JP; Garon, EB; Gernhardt, D; Giri, N; Jatoi, A; Keefe, DM; Kim, DW; Lacouture, ME; Nadanaciva, S; O'Connell, J; Sbar, E; Sonis, S; Wang, T | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Migliorino, MR; Mok, TS; Nadanaciva, S; Nakagawa, K; Niho, S; Pluzanski, A; Rosell, R; Sandin, R; Sbar, EI; Tsuji, F; Wang, T; White, JL; Wu, YL; Zhou, X | 1 |
| Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Chen, F; Dai, D; Ji, W; Meng, D; Shen, J; Wang, B; Wang, C; Wang, S; Zhou, Q; Zhou, Y | 1 |
8 review(s) available for quinazolines and pf 00299804
| Article | Year |
|---|---|
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines | 2010 |
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2014 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
7 trial(s) available for quinazolines and pf 00299804
| Article | Year |
|---|---|
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2012 |
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Quinazolinones; Treatment Failure | 2014 |
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2014 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Quinazolinones; Republic of Korea; Treatment Outcome | 2017 |
Dacomitinib Beats Gefitinib for EGFR
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2017 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Prognosis; Quinazolines; Quinazolinones; Survival Analysis; Treatment Outcome | 2017 |
15 other study(ies) available for quinazolines and pf 00299804
| Article | Year |
|---|---|
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cloning, Molecular; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Quinazolines; Quinazolinones | 2007 |
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2010 |
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Inhibitory Concentration 50; Lapatinib; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Quinazolinones; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab | 2012 |
KRAS wild-type lung cancer: a moving target in an era of genotype migration.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Topics: Afatinib; Animals; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Stromal Cells; Xenograft Model Antitumor Assays | 2012 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Signal Transduction; Tumor Cells, Cultured | 2013 |
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2014 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2016 |
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Topics: Alternative Splicing; Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Inhibitory Concentration 50; Lapatinib; Mammary Neoplasms, Experimental; Mice, Transgenic; Phenotype; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptor, ErbB-2; Signal Transduction; Time Factors | 2016 |
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; ErbB Receptors; Heterografts; Humans; Injections, Intravenous; Macaca fascicularis; Male; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyridines; Pyrimidines; Quinazolines; Quinazolinones; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2016 |
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Topics: Afatinib; Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Codon; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice; Models, Molecular; Molecular Conformation; Mutagenesis; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Structure-Activity Relationship | 2017 |
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins | 2017 |
Effects of dacomitinib on the pharmacokinetics of poziotinib
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Humans; Inhibitory Concentration 50; Microsomes, Liver; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2021 |